Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Alzheimer’s disease

FDA Clears First Alzheimer’s Blood Test, Lending ‘Momentum’ to Lilly’s Kisunla, Biogen’s Leqembi

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s disease therapies.

May 19, 2025

2 min read

Tristan Manalac

Sponsored

A Smarter, Faster Path to Patient-Centered Research

The Shift Toward Real-World, Patient-Centered Evidence

May 19, 2025

4 min read

illustration of man lost in a maze full of arrows, surreal abstract concept

FDA

Makary’s ‘Conditional Approval’ Pathway for Rare Diseases Poses More Questions Than Answers

While sparking excitement among biopharma companies focused on rare and ultrarare indications, experts say FDA Commissioner Marty Makary’s proposal is light on details and raises potential concerns about safety, access and liability.

May 19, 2025

10 min read

Heather McKenzie

Tools needed to carry out scientific experiments in biology and chemistry. Modern vector illustration on a red background.

Clinical Research

FDA, NIH Accelerate Shift Away From Animal Research as Experts Warn of Limitations

The FDA and NIH recently announced plans to phase out animal testing requirements for some therapies. While organoid and AI providers celebrate, scientists warn that questions over safety, applicability and implementation remain.

May 19, 2025

6 min read

Natalia Mesa

Circular handsaw cutting through a strip of red tape

Opinion

Slashing FDA Regulations Is Unlikely to Save Money for Industry

While the Trump administration has painted the jettisoning of staff and regulations as good for business, there are multiple reasons it’s unlikely to work out that way.

May 19, 2025

4 min read

Jessica Taylor

Illustration of two arrows merging into one

Mergers & acquisitions

BioMarin Expands Enzyme Expertise With $270M Inozyme Buy

The star of the acquisition is the enzyme replacement therapy INZ-701, being developed for the rare disease ENPP1 deficiency.

May 16, 2025

2 min read

Tristan Manalac

Approvals

Incyte’s PD-1 Blocker Wins First-Line Anal Cancer Approval

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are intolerant to platinum chemotherapy or whose disease has progressed.

May 16, 2025

2 min read

Tristan Manalac

Duchenne muscular dystrophy

Sarepta Seeks to Strengthen Elevidys’ Case With Data in Older Kids

Since Elevidys’ accelerated approval in 2023, experts have been clamoring for more data, particularly in older and non-ambulatory children. New results, presented Friday, show mobility improvements in 8- to 9-year-old patients after one year of follow-up.

May 16, 2025

2 min read

Tristan Manalac